Durable Near-Complete Response to Pembrolizumab-Chemotherapy in BRAF Wild-Type Thyroid Cancer

The source does not report the patient's age or sex. The reported diagnosis was anaplastic thyroid cancer that was BRAF V600E wild-type (lacking this specific mutation) and PD-L1-positive, with a tumor proportion score of 80% on immunohistochemistry, meaning 80% of tumor cells stained positive for this checkpoint protein.

The case report documents residual or relapsed disease following surgical treatment for anaplastic thyroid cancer. Specific details of the surgical procedure, extent of disease at relapse, and symptoms are not described in the available source material.

Molecular testing identified the tumor as BRAF V600E wild-type, meaning it did not carry this common activating mutation found in a subset of anaplastic thyroid cancers. PD-L1 immunohistochemistry showed a tumor proportion score of 80%, classifying the tumor as PD-L1-positive with high expression. Cancer stage and specific histologic subtype were not further detailed in the source.

The patient underwent surgery, after which residual or relapsed disease was identified. This was followed by treatment with a multi-targeted tyrosine kinase inhibitor, an oral drug that blocks multiple growth-signaling enzymes at once; the specific agent was not named in the source. After disease progression on this therapy, the patient began pembrolizumab, an antibody that blocks the PD-1 immune checkpoint protein to help the immune system attack tumor cells, combined with the chemotherapy drugs nab-paclitaxel and carboplatin.

Following initiation of the pembrolizumab, nab-paclitaxel, and carboplatin combination, the case report describes a near-complete response, meaning tumor burden was reduced to a very small residual amount without disappearing entirely as measured by imaging or clinical assessment. Specific quantitative tumor measurements or imaging findings were not detailed in the available source.

The near-complete response was sustained for over 30 months of follow-up. The source reports that the safety profile of the triplet regimen was manageable, though specific adverse events and their severity grades were not detailed.

This case's biology centers on two features documented together but not mechanistically linked by the available evidence: BRAF V600E wild-type status and high PD-L1 expression. Genomic studies of BRAF wild-type anaplastic thyroid cancer describe alternative drivers such as RAS, TP53, PIK3CA, TERT promoter, and PI3K/AKT/mTOR pathway alterations, distinguishing this molecular subtype from BRAF-mutant tumors that can be treated with BRAF/MEK inhibitors. This genomic context helps explain the reliance on a non-selective multi-targeted tyrosine kinase inhibitor rather than a driver-targeted agent, and its eventual failure, though no evidence here directly demonstrates the mechanism of that failure. The subsequent near-complete response to pembrolizumab plus nab-paclitaxel and carboplatin aligns with a body of evidence, from a different anti-PD-1 agent in anaplastic thyroid cancer and from other PD-L1-selected tumor types treated with pembrolizumab-chemotherapy combinations, that high PD-L1 expression can accompany strong and durable responses to checkpoint blockade-based regimens. However, a cross-indication review found PD-L1 immunohistochemistry to be an inconsistent predictor of response across approved checkpoint inhibitor uses, and separate evidence suggests the pathway linking BRAF signaling to PD-L1 upregulation described in papillary thyroid carcinoma does not obviously apply to this BRAF wild-type tumor. Taken together, the evidence is compatible with, but does not confirm, a model in which high PD-L1 expression contributed to this durable response through a mechanism distinct from BRAF-driven immune evasion.

This case illustrates a favorable outcome in a treatment scenario where genomic and immune biology only partially explain what was observed. The absence of an actionable BRAF V600E mutation removed one therapeutic avenue, BRAF/MEK inhibition, that has produced high response rates in BRAF-mutant anaplastic thyroid cancer, and instead directed treatment toward broader targeted and then immune-based approaches. The eventual combination of pembrolizumab with nab-paclitaxel and carboplatin draws indirect support from analogous regimens in other PD-L1-positive cancers, where platinum or taxane chemotherapy paired with checkpoint blockade improved outcomes relative to chemotherapy alone, but none of that evidence comes from anaplastic thyroid cancer itself, and no study identified examines this exact three-drug combination in this tumor type. The high PD-L1 score is a plausible contributor to the depth and durability of response observed, consistent with data from a PD-1 blockade basket trial in the same cancer type, yet the broader literature on PD-L1 as a biomarker across cancers shows it is an imperfect predictor, and separate thyroid cancer literature suggests immune infiltrate and inflammatory signaling do not uniformly favor treatment response. This leaves open the possibility that other undocumented tumor or host factors contributed to this outcome. The case is informative as an example of a durable response occurring under a particular combination of molecular features, rather than as confirmation of a generalizable predictive rule linking BRAF wild-type status, PD-L1 positivity, and triplet chemo-immunotherapy outcomes.

This analysis is based on a single published case, which by design cannot establish how frequently similar responses occur in comparable patients, nor can it exclude the role of chance or unreported clinical factors, such as prior treatment details, comorbidities, or specific chemotherapy dosing, that were not captured in the source. Much of the supporting evidence for the biological reasoning presented here comes from other tumor types (lung cancer, breast cancer) or from a different anti-PD-1 agent in the same cancer type, and cross-tumor-type extrapolation carries inherent uncertainty given known differences in immune and genomic biology between cancers. The evidence search underlying this analysis was limited to a defined set of sources and evidence types; it is not an exhaustive systematic review of anaplastic thyroid cancer immunotherapy literature, and additional relevant studies may exist outside the scope reviewed here. As a secondary analysis of a published case, this write-up cannot verify details beyond what the original source reported, including cancer stage, patient demographics, or specific imaging findings.

The available case report does not include the patient's own account of their diagnosis, treatment decision-making, symptom experience, or quality of life during therapy.